Supplementary Figure 3 from Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing
journal contribution
posted on 2023-03-30, 21:55 authored by Ellen Heitzer, Martina Auer, Christin Gasch, Martin Pichler, Peter Ulz, Eva Maria Hoffmann, Sigurd Lax, Julie Waldispuehl-Geigl, Oliver Mauermann, Carolin Lackner, Gerald Höfler, Florian Eisner, Heinz Sill, Hellmut Samonigg, Klaus Pantel, Sabine Riethdorf, Thomas Bauernhofer, Jochen B. Geigl, Michael R. SpeicherPDF file - 1303K, Evaluation of available material from patient #9. (a-b) Array CGH profiles of the primary tumor (a) and metastasis (peritoneal carcinomatosis) (b). Regarding the color bar codes please see legend to Supp. Fig. 2.
History
ARTICLE ABSTRACT
Circulating tumor cells (CTC) released into blood from primary cancers and metastases reflect the current status of tumor genotypes, which are prone to changes. Here, we conducted the first comprehensive genomic profiling of CTCs using array–comparative genomic hybridization (CGH) and next-generation sequencing. We used the U.S. Food and Drug Administration–cleared CellSearch system, which detected CTCs in 21 of 37 patients (range, 1–202/7.5 mL sample) with stage IV colorectal carcinoma. In total, we were able to isolate 37 intact CTCs from six patients and identified in those multiple colorectal cancer–associated copy number changes, many of which were also present in the respective primary tumor. We then used massive parallel sequencing of a panel of 68 colorectal cancer–associated genes to compare the mutation spectrum in the primary tumors, metastases, and the corresponding CTCs from two of these patients. Mutations in known driver genes [e.g., adenomatous polyposis coli (APC), KRAS, or PIK3CA] found in the primary tumor and metastasis were also detected in corresponding CTCs. However, we also observed mutations exclusively in CTCs. To address whether these mutations were derived from a small subclone in the primary tumor or represented new variants of metastatic cells, we conducted additional deep sequencing of the primary tumor and metastasis and applied a customized statistical algorithm for analysis. We found that most mutations initially found only in CTCs were also present at subclonal level in the primary tumors and metastases from the same patient. This study paves the way to use CTCs as a liquid biopsy in patients with cancer, providing more effective options to monitor tumor genomes that are prone to change during progression, treatment, and relapse. Cancer Res; 73(10); 2965–75. ©2013 AACR.Usage metrics
Keywords
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC